Hoth Therapeutics Inc. has announced ongoing progress in its clinical and preclinical therapeutic pipeline. The company is advancing HT-001, a topical epidermal growth factor inhibitor, in the Phase 2 CLEER-001 clinical trial for EGFR-inhibitor-associated rash in oncology supportive care. A further clinical data update is anticipated in the coming months as enrollment continues. Additionally, Hoth's HT-KIT program, targeting mast cell diseases and granted FDA Orphan Drug Designation, is nearing completion of IND-enabling toxicology studies, with an Investigational New Drug $(IND)$ filing planned. No finalized clinical results have been presented at this time; updates are expected as the studies progress.